key: cord-0710825-cs5yv8z4
authors: Goodhue Meyer, Erin K.; Xu, Meng; Lasky, Baia; Young, Pampee P.
title: Seroreactivity with COVID‐19 antibody testing in CCP donors presenting without a SARS‐CoV‐2 diagnostic test
date: 2020-11-02
journal: Transfusion
DOI: 10.1111/trf.16146
sha: 33cd84fca471b8f60831dee561e74a163c7c087f
doc_id: 710825
cord_uid: cs5yv8z4

nan

On March 24, 2020, the US Food and Drug Administration announced an investigational initiative to transfuse convalescent plasma (CCP) from patients recovered from coronavirus disease 2019 (COVID-19) to treat patients suffering from severe COVID-19 1 . Initial eligibility criteria required donors to have evidence of past severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by a positive molecular diagnostic test of upper respiratory sample (ie, nasopharyngeal [NP] swab), blood positive for SARS-CoV-2 RNA, or a positive serologic test 1 . Minimum antibody titers or evidence of neutralizing antibodies were reported if testing was able to be performed but was not required with sample storage for future testing. 2 Donors also needed to be at least 14 days from resolution of clinical symptoms and had to meet allogeneic blood donor criteria per the Code of Federal Regulations. 2 The American Red Cross (ARC) mobilized CCP collection efforts at the end of March 2020. Serologic testing for antibodies to the SARS-CoV-2 spike glycoprotein using a semiquantitative enzyme-linked immunosorbent assay (VITROS Anti-SARS-CoV-2 Total Test; Ortho Clinical Diagnostics, Raritan, New Jersey) was instituted for CCP donors on 27 April 2020. 3 After implementation, only units from donors with a signal-to-cutoff (S/CO) ratio of 1.0 or greater (reactive per package insert) were labeled as CCP units. 3 The ARC had an evolutionary approach to donor qualification. At first, an initially positive NP swab (or a physician's attestation) with date of symptom resolution were required. Donors 14 to 28 days from symptom resolution required a follow-up negative NP swab. Following serologic testing implementation, the ARC transitioned to qualifying donors without requiring diagnostic test proof, allowing donors to self-report previous diagnostic testing positivity. All donors needed to have had a symptomatic COVID-19 infection and be at least 14 days from symptom resolution.

Between diagnostic testing and more than 28 days from symptom resolution. A total of 36.4% of donors without diagnostic testing had a reactive VITROS test, with an overall median S/CO of 0.11 (Table 1) . Among the donors with diagnostic testing, the early recovery group had 82.3% reactivity (overall median S/CO, 26.2). Those further in recovery had 91.9% (overall median S/CO, 129.5). Statistically, by χ 2 analysis, the percentage of donors with reactivity was significantly different among the three groups (P < .0001), and Kruskal-Wallis tests demonstrated statistical significance in S/CO values among the groups (P < .0001). Our seroreactivity evaluation in CCP donors presenting with and without a diagnostic COVID-19 PCR test highlights the importance of testing to enrich for donors with SARS-CoV-2 antibodies. There were a few notable limitations to our study, including screening with only one testing platform examining a single immune response target to SARS-CoV-2 infection. This was a small study with a limited number of donors. The three groups were in different states of recovery but in this cohort, lack of diagnostic testing had the most pronounced effect on seroreactivity. Finally, this represents the experience of a single, large blood collector. Due to limitations of collection capacity, it is important to ensure the CCP population is likely to be COVID-19 antibody enriched. This information may be of value to other CCP collectors recruiting CCP donors and building inventory.

CCP, convalescent plasma, COVID-19, donor, SARS-CoV-2

Recommendations for Investigational COVID-19 Convalescent Plasma, the Food and Drug Administration

Code of Federal Regulations. Title 21, CFR Parts 600 to 799

VITROS immunodiagnostic products anti-SARS-CoV-2 Total reagent pack and VITROS immunodiagnostic products anti-SARS-CoV-2 Total calibrator instructions for use

The authors declare no conflict of interest.